Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 21, 2017
What is the competitive landscape for CEPHALON, and when can generic versions of CEPHALON drugs launch?
CEPHALON has eight approved drugs.| International Patents: | 185 |
| US Patents: | 27 |
| Tradenames: | 8 |
| Ingredients: | 6 |
| NDAs: | 8 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
arsenic trioxide | Injection | 1 mg/mL | TRISENOX | 8/11/2015 |
bendamustine hydrochloride | Injection | 90 mg/mL, 0.5 mL and 2 mL in single-dose vials | TREANDA | 6/19/2014 |
tiagabine hydrochloride | Tablets | 12 mg and 16 mg | GABITRIL | 1/24/2014 |
bendamustine hydrochloride | Injection | 25 mg/vial and 100 mg/vial | TREANDA | 6/4/2013 |
armodafinil | Tablets | 100 mg and 200 mg | NUVIGIL | 9/11/2009 |
fentanyl citrate | Buccal Tablets | 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg | FENTORA | 11/13/2007 |
tiagabine hydrochloride | Tablets | 2 mg and 4 mg | GABITRIL | 2/1/2005 |
fentanyl citrate | Lozenges | 0.6 mg | ACTIQ | 12/20/2004 |
fentanyl citrate | Lozenges | 0.8 mg, 1.2 mg and 1.6 mg | ACTIQ | 11/22/2004 |
fentanyl citrate | Lozenges | 0.2 mg | ACTIQ | 10/29/2004 |
fentanyl citrate | Lozenges | 0.4 mg | ACTIQ | 10/6/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,461,350 | Bendamustine pharmaceutical compositions | ► Subscribe | |||||||||||||
| 6,641,838 | Effervescent drug delivery system for oral administration | ► Subscribe | |||||||||||||
| 6,350,470 | Effervescent drug delivery system for oral administration | ► Subscribe | |||||||||||||
| 6,770,304 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | ► Subscribe | |||||||||||||
| 7,879,364 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | ► Subscribe | |||||||||||||
| 8,298,577 | Effervescent oral opiate dosage forms and methods of administering opiates | ► Subscribe | |||||||||||||
| 7,858,121 | Effervescent oral fentanyl dosage form and methods of administering fentanyl | ► Subscribe | |||||||||||||
| 6,509,036 | Effervescent drug delivery system for oral administration | ► Subscribe | |||||||||||||
| 6,576,250 | Pharmaceutical compositions for rectal and vaginal administration | ► Subscribe | |||||||||||||
| 6,764,696 | Effervescent drug delivery system for oral administration | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiwan | I380830 | ► Subscribe | |||||||||||||
| Japan | 5685611 | ► Subscribe | |||||||||||||
| Canada | 2548915 | ► Subscribe | |||||||||||||
| Australia | 747474 | ► Subscribe | |||||||||||||
| Brazil | 9814857 | ► Subscribe | |||||||||||||
| Spain | 2360114 | ► Subscribe | |||||||||||||
| Japan | 5688195 | ► Subscribe | |||||||||||||
| Spain | 2324908 | ► Subscribe | |||||||||||||
| Denmark | 1964557 | ► Subscribe | |||||||||||||
| Japan | 2007517053 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0107 | Belgium | ► Subscribe | PRODUCT NAME: TIAGABINE CHLORHYDRATE MONOHYDRATE - TIAGABINE ANHYDRE; NAT. REGISTRATION NO/DATE: 403 IS 102 F 3 19970602; FIRST REGISTRATION: FR 341 260.2 19960614 | ||||||||||||
| C/GB98/022 | United Kingdom | ► Subscribe | PRODUCT NAME: TIAGABINE ( INCLUDING SALTS THEREOF ); REGISTERED: FR AMM NO. 341 260.2 19960614; FR AMM NO. 341 262.5 19960614; FR AMM NO. 341 264.8 19960614; UK 03132/0117 19971111; UK 03132/0118 19971111; UK 03132/0119 19971111 | ||||||||||||
| 00521 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 | ||||||||||||
| 00653 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 | ||||||||||||
| C/GB06/022 | United Kingdom | ► Subscribe | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 | ||||||||||||
| 2011000009 | Germany | ► Subscribe | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 | ||||||||||||
| 2014 00016 | Denmark | ► Subscribe | PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831 | ||||||||||||
| 2006000022 | Germany | ► Subscribe | PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126 | ||||||||||||
| 00522 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006 | ||||||||||||
| 2014000024 | Germany | ► Subscribe | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,980 others who get our Drug Patent Expiration Alerts:
